Molecular classifications of gastric cancers: Novel insights and possible future applications

Silvio Ken Garattini, Debora Basile, Monica Cattaneo, Valentina Fanotto, Elena Ongaro, Marta Bonotto, Francesca V. Negri, Rosa Berenato, Paola Ermacora, Giovanni Gerardo Cardellino, Mariella Giovannoni, Nicoletta Pella, Mario Scartozzi, Lorenzo Antonuzzo, Nicola Silvestris, Gianpiero Fasola, Giuseppe Aprile

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Despite some notable advances in the systemic management of gastric cancer (GC), the prognosis of patients with advanced disease remains overall poor and their chance of cure is anecdotic. In a molecularly selected population, a median overall survival of 13.8 mo has been reached with the use of human epidermal growth factor 2 (HER2) inhibitors in combination with chemotherapy, which has soon after become the standard of care for patients with HER2-overexpressing GC. Moreover, oncologists have recognized the clinical utility of conceiving cancers as a collection of different molecularlydriven entities rather than a single disease. Several molecular drivers have been identified as having crucial roles in other tumors and new molecular classifications have been recently proposed for gastric cancer as well. Not only these classifications allow the identification of different tumor subtypes with unique features, but also they serve as springboard for the development of different therapeutic strategies. Hopefully, the application of standard systemic chemotherapy, specific targeted agents, immunotherapy or even surgery in specific cancer subgroups will help maximizing treatment outcomes and will avoid treating patients with minimal chance to respond, therefore diluting the average benefit. In this review, we aim at elucidating the aspects of GC molecular subtypes, and the possible future applications of such molecular analyses.

Original languageEnglish
Pages (from-to)194-208
Number of pages15
JournalWorld Journal of Gastrointestinal Oncology
Volume9
Issue number5
DOIs
Publication statusPublished - May 1 2017

Fingerprint

Stomach Neoplasms
Epidermal Growth Factor
Neoplasms
Standard of Care
Combination Drug Therapy
Immunotherapy
Drug Therapy
Survival
Population
Therapeutics

Keywords

  • Classification
  • Gastric cancer
  • Immunotherapy
  • Molecular biology
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Molecular classifications of gastric cancers : Novel insights and possible future applications. / Garattini, Silvio Ken; Basile, Debora; Cattaneo, Monica; Fanotto, Valentina; Ongaro, Elena; Bonotto, Marta; Negri, Francesca V.; Berenato, Rosa; Ermacora, Paola; Cardellino, Giovanni Gerardo; Giovannoni, Mariella; Pella, Nicoletta; Scartozzi, Mario; Antonuzzo, Lorenzo; Silvestris, Nicola; Fasola, Gianpiero; Aprile, Giuseppe.

In: World Journal of Gastrointestinal Oncology, Vol. 9, No. 5, 01.05.2017, p. 194-208.

Research output: Contribution to journalArticle

Garattini, SK, Basile, D, Cattaneo, M, Fanotto, V, Ongaro, E, Bonotto, M, Negri, FV, Berenato, R, Ermacora, P, Cardellino, GG, Giovannoni, M, Pella, N, Scartozzi, M, Antonuzzo, L, Silvestris, N, Fasola, G & Aprile, G 2017, 'Molecular classifications of gastric cancers: Novel insights and possible future applications', World Journal of Gastrointestinal Oncology, vol. 9, no. 5, pp. 194-208. https://doi.org/10.4251/wjgo.v9.i5.194
Garattini, Silvio Ken ; Basile, Debora ; Cattaneo, Monica ; Fanotto, Valentina ; Ongaro, Elena ; Bonotto, Marta ; Negri, Francesca V. ; Berenato, Rosa ; Ermacora, Paola ; Cardellino, Giovanni Gerardo ; Giovannoni, Mariella ; Pella, Nicoletta ; Scartozzi, Mario ; Antonuzzo, Lorenzo ; Silvestris, Nicola ; Fasola, Gianpiero ; Aprile, Giuseppe. / Molecular classifications of gastric cancers : Novel insights and possible future applications. In: World Journal of Gastrointestinal Oncology. 2017 ; Vol. 9, No. 5. pp. 194-208.
@article{db59731a854e4b16933d2c46e1aa119c,
title = "Molecular classifications of gastric cancers: Novel insights and possible future applications",
abstract = "Despite some notable advances in the systemic management of gastric cancer (GC), the prognosis of patients with advanced disease remains overall poor and their chance of cure is anecdotic. In a molecularly selected population, a median overall survival of 13.8 mo has been reached with the use of human epidermal growth factor 2 (HER2) inhibitors in combination with chemotherapy, which has soon after become the standard of care for patients with HER2-overexpressing GC. Moreover, oncologists have recognized the clinical utility of conceiving cancers as a collection of different molecularlydriven entities rather than a single disease. Several molecular drivers have been identified as having crucial roles in other tumors and new molecular classifications have been recently proposed for gastric cancer as well. Not only these classifications allow the identification of different tumor subtypes with unique features, but also they serve as springboard for the development of different therapeutic strategies. Hopefully, the application of standard systemic chemotherapy, specific targeted agents, immunotherapy or even surgery in specific cancer subgroups will help maximizing treatment outcomes and will avoid treating patients with minimal chance to respond, therefore diluting the average benefit. In this review, we aim at elucidating the aspects of GC molecular subtypes, and the possible future applications of such molecular analyses.",
keywords = "Classification, Gastric cancer, Immunotherapy, Molecular biology, Targeted therapy",
author = "Garattini, {Silvio Ken} and Debora Basile and Monica Cattaneo and Valentina Fanotto and Elena Ongaro and Marta Bonotto and Negri, {Francesca V.} and Rosa Berenato and Paola Ermacora and Cardellino, {Giovanni Gerardo} and Mariella Giovannoni and Nicoletta Pella and Mario Scartozzi and Lorenzo Antonuzzo and Nicola Silvestris and Gianpiero Fasola and Giuseppe Aprile",
year = "2017",
month = "5",
day = "1",
doi = "10.4251/wjgo.v9.i5.194",
language = "English",
volume = "9",
pages = "194--208",
journal = "World J Gastrointest Oncol",
number = "5",

}

TY - JOUR

T1 - Molecular classifications of gastric cancers

T2 - Novel insights and possible future applications

AU - Garattini, Silvio Ken

AU - Basile, Debora

AU - Cattaneo, Monica

AU - Fanotto, Valentina

AU - Ongaro, Elena

AU - Bonotto, Marta

AU - Negri, Francesca V.

AU - Berenato, Rosa

AU - Ermacora, Paola

AU - Cardellino, Giovanni Gerardo

AU - Giovannoni, Mariella

AU - Pella, Nicoletta

AU - Scartozzi, Mario

AU - Antonuzzo, Lorenzo

AU - Silvestris, Nicola

AU - Fasola, Gianpiero

AU - Aprile, Giuseppe

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Despite some notable advances in the systemic management of gastric cancer (GC), the prognosis of patients with advanced disease remains overall poor and their chance of cure is anecdotic. In a molecularly selected population, a median overall survival of 13.8 mo has been reached with the use of human epidermal growth factor 2 (HER2) inhibitors in combination with chemotherapy, which has soon after become the standard of care for patients with HER2-overexpressing GC. Moreover, oncologists have recognized the clinical utility of conceiving cancers as a collection of different molecularlydriven entities rather than a single disease. Several molecular drivers have been identified as having crucial roles in other tumors and new molecular classifications have been recently proposed for gastric cancer as well. Not only these classifications allow the identification of different tumor subtypes with unique features, but also they serve as springboard for the development of different therapeutic strategies. Hopefully, the application of standard systemic chemotherapy, specific targeted agents, immunotherapy or even surgery in specific cancer subgroups will help maximizing treatment outcomes and will avoid treating patients with minimal chance to respond, therefore diluting the average benefit. In this review, we aim at elucidating the aspects of GC molecular subtypes, and the possible future applications of such molecular analyses.

AB - Despite some notable advances in the systemic management of gastric cancer (GC), the prognosis of patients with advanced disease remains overall poor and their chance of cure is anecdotic. In a molecularly selected population, a median overall survival of 13.8 mo has been reached with the use of human epidermal growth factor 2 (HER2) inhibitors in combination with chemotherapy, which has soon after become the standard of care for patients with HER2-overexpressing GC. Moreover, oncologists have recognized the clinical utility of conceiving cancers as a collection of different molecularlydriven entities rather than a single disease. Several molecular drivers have been identified as having crucial roles in other tumors and new molecular classifications have been recently proposed for gastric cancer as well. Not only these classifications allow the identification of different tumor subtypes with unique features, but also they serve as springboard for the development of different therapeutic strategies. Hopefully, the application of standard systemic chemotherapy, specific targeted agents, immunotherapy or even surgery in specific cancer subgroups will help maximizing treatment outcomes and will avoid treating patients with minimal chance to respond, therefore diluting the average benefit. In this review, we aim at elucidating the aspects of GC molecular subtypes, and the possible future applications of such molecular analyses.

KW - Classification

KW - Gastric cancer

KW - Immunotherapy

KW - Molecular biology

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85028408934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028408934&partnerID=8YFLogxK

U2 - 10.4251/wjgo.v9.i5.194

DO - 10.4251/wjgo.v9.i5.194

M3 - Article

AN - SCOPUS:85028408934

VL - 9

SP - 194

EP - 208

JO - World J Gastrointest Oncol

JF - World J Gastrointest Oncol

IS - 5

ER -